12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
Study sponsor: Tonix Pharmaceuticals, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2018-07-27Actual
Enrollment · participants190Actual
Source updated2025-02-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.